The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of adults with ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult ...

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

Johnson & Johnson (JNJ) gains FDA approval to expand the labeling for its monoclonal antibody Tremfya for ulcerative colitis.

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third ...

Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults ...

The US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults with moderately to ...